Personalized Medicine News and Research

RSS

2010 BIO International Convention to discuss issues that impact drug discovery and development

The 2010 BIO International Convention will feature a robust health and medical program highlighting the latest scientific breakthroughs and policy and business development issues that impact drug discovery and development. Hosted by the Biotechnology Industry Organization, the Convention will be held May 3-6, 2010 in Chicago, Ill. at McCormick Place.

31 Mar 2010

BioNanomatrix awarded patent covering nanochannel arrays for high-throughput macromolecular analysis

BioNanomatrix, Inc., a developer of breakthrough single-molecule genomic analysis technology, today announced the issuance of U.S. patent 7,670,770 for nanochannel arrays that enable high-throughput macromolecular analysis. Also disclosed are methods of preparing nanochannel array chips, methods of analyzing macromolecules such as entire strands of genomic DNA, and systems for implementing these methods.

31 Mar 2010

Fairbanks Institute and BioServe to co-market next generation biorepository, INbank

The Fairbanks Institute for Healthy Communities, the Indianapolis not-for-profit organization working to improve community health, and BioServe, a global provider of biomaterial and genetic research services, today announced that they will co-market INbank™, a next generation biorepository that was recently launched by The Fairbanks Institute.

31 Mar 2010

New data on EHT 0202 for treatment of patients with AD presented at Geneva/Springfield Symposium

ExonHit Therapeutics announced today that promising new data on EHT 0202, its lead candidate in Alzheimer's disease, were presented at the 11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy from March 24th to March 27th in Geneva, Switzerland.

29 Mar 2010

UAB researchers discover first bio-marker for MS

Researchers at the University of Alabama at Birmingham have found the first bio-marker for multiple sclerosis that might predict which patients will respond to a standard therapy and which will not.

29 Mar 2010

Palex Medical to distribute Genomic Health's Oncotype DX breast cancer test in Spain and Portugal

Genomic Health, Inc. today announced that the company has entered into an exclusive agreement with Palex Medical S.A., one of Europe's leading distributors of medical device and diagnostic services to hospitals, to distribute its Oncotype DX® breast cancer test in Spain and Portugal. The distribution agreement, announced in conjunction with positive data presented today at the 7th European Breast Cancer Conference (EBCC), further expands the global presence of Oncotype DX, providing for increased physician and patient access to this advanced diagnostic test in the European market.

26 Mar 2010

ASCO, ESMO and OECI endorse WIN Symposium's initiatives on improving outcomes of cancer

The WIN Consortium, supported by its media partner Nature Publishing Group, has opened registration for the second annual WIN Symposium, to be held in the Palais des Congrès, Paris, on the 7th to 9th of July 2010. The WIN Symposium is an open and interactive forum designed to promote rapid translation of ground-breaking personalized cancer medicine discoveries to clinical practice.

25 Mar 2010

Clinical Reference Laboratory completes validation testing of DNA Genotek's Oragene-DNA saliva collection kits

Clinical Reference Laboratory today announced that it has completed validation testing of DNA Genotek's Oragene-DNA saliva collection kits and will adopt Oragene-DNA for use with its molecular diagnostic services.

25 Mar 2010

Nodality raises $15.5M to support launch of acute myelogenous leukemia test

Nodality, Inc., a biotechnology company focused on the development of next generation personalized medicine tests in cancer and autoimmune disease, today announced it completed financing in which the company raised $15.5 million.

23 Mar 2010

‘Young Minds’ program for graduate and post-doctoral students

The Regenerative Medicine Foundation is pleased to announce a special "Young Minds" graduate student registration rate for its annual Translational Regenerative Medicine Forum, set for April 6-8 in Winston-Salem.

20 Mar 2010

Major study shoots for personalized breast cancer drugs

Mutations in BCRA1 and BCRA2 genes are mainly associated with increased risk of breast cancer in women. Recently many other genetic variants have been found to be associated with breast cancer.

19 Mar 2010

Prometheus Laboratories, Bayer Schering Pharma form research collaboration and license agreement

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a research collaboration and license agreement with Bayer Schering Pharma AG, Germany, a worldwide leading specialty pharmaceutical company. The collaboration partners Prometheus' proprietary oncology diagnostic platform with Bayer's broad oncology pipeline in an effort to stratify patients to appropriate drug candidates and potentially accelerate the development of novel oncology therapeutic products.

18 Mar 2010

Virtuoso Digital Pathology Software: BioImagene adds Companion Algorithms for colon cancer

BioImagene, Inc., the leading provider of end-to-end digital pathology solutions, today announced the availability of Companion Algorithms™ for colon cancer in their Virtuoso™ Digital Pathology Software. BioImagene’s Companion Algorithms are unique in the digital pathology industry as they are specific to a biomarker and a tissue type. Therefore, pathologists are not faced with the challenges of customizing generic algorithms in order to make them work.

18 Mar 2010

Enzo Biochem announces supply and distribution agreement between Enzo Life Sciences and Cancer Genetics

Enzo Biochem, Inc., a vertically integrated biotechnology company engaged in the research, development, manufacture, licensing and marketing of innovative health care products, platforms and services based on molecular and cellular technologies, announced today a supply and distribution agreement between Enzo Life Sciences and privately-owned Cancer Genetics Inc., a leading producer of nucleic acid products used in genomic research.

18 Mar 2010

I-SPY 2: The Biomarkers Consortium launches clinical trial for high risk, fast-growing breast cancers

The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.

18 Mar 2010

HDC, SPM enter into development and licensing agreements with Quest Diagnostics

Health Discovery Corporation and Smart Personalized Medicine, LLC announced today that they have entered into development and related licensing agreements with Quest Diagnostics Incorporated, the world’s leading provider of diagnostic testing, information and services.

From Quest Diagnostics 17 Mar 2010

PAREXEL genotypes over 10,000 potential study participants to identify 400 CYP2D6 poor metabolizers

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has completed a large and complex pharmacogenetics-based early phase study. The study was conducted in a healthy volunteer population of poor metabolizers of Cytochrome P450 2D6 (CYP2D6), an important enzyme involved in the metabolism of drugs. The study monitored the QTc interval following administration of a neurological treatment, which has been shown to have a higher drug exposure in poor metabolizers of CYP2D6.

From Parexel 17 Mar 2010

Clarient's Ovotax test may help improve patients’ response to taxane therapy

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that data from a new study shows that Clarient's Ovotax™ assay may effectively predict which ovarian cancer patients will respond favorably to taxane therapy and could, therefore, be spared the potential side effects of this rigorous and sometimes toxic chemotherapy agent.

17 Mar 2010

Human amniotic fluid skin cells "reprogrammed" to pluripotency

In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.

16 Mar 2010

Itamar, Roche sign agreement to use EndoPAT device in phase II study for patients with PAD

Itamar announced today that it signed an agreement with Roche for use of Itamar’s EndoPAT device in a clinical phase II study for patients with Peripheral Arterial Disease (PAD) at 80 worldwide medical centers.

16 Mar 2010

Personalized Medicine News and Research

2010 BIO International Convention to discuss issues that impact drug discovery and development

BioNanomatrix awarded patent covering nanochannel arrays for high-throughput macromolecular analysis

Fairbanks Institute and BioServe to co-market next generation biorepository, INbank

New data on EHT 0202 for treatment of patients with AD presented at Geneva/Springfield Symposium

UAB researchers discover first bio-marker for MS

Palex Medical to distribute Genomic Health's Oncotype DX breast cancer test in Spain and Portugal

ASCO, ESMO and OECI endorse WIN Symposium's initiatives on improving outcomes of cancer

Clinical Reference Laboratory completes validation testing of DNA Genotek's Oragene-DNA saliva collection kits

Nodality raises $15.5M to support launch of acute myelogenous leukemia test

‘Young Minds’ program for graduate and post-doctoral students

Major study shoots for personalized breast cancer drugs

Prometheus Laboratories, Bayer Schering Pharma form research collaboration and license agreement

Virtuoso Digital Pathology Software: BioImagene adds Companion Algorithms for colon cancer

Enzo Biochem announces supply and distribution agreement between Enzo Life Sciences and Cancer Genetics

I-SPY 2: The Biomarkers Consortium launches clinical trial for high risk, fast-growing breast cancers

HDC, SPM enter into development and licensing agreements with Quest Diagnostics

PAREXEL genotypes over 10,000 potential study participants to identify 400 CYP2D6 poor metabolizers

Clarient's Ovotax test may help improve patients’ response to taxane therapy

Human amniotic fluid skin cells "reprogrammed" to pluripotency

Itamar, Roche sign agreement to use EndoPAT device in phase II study for patients with PAD

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News